CVN424 Monotherapy for Early Parkinson's Disease

Recruiting in Palo Alto (17 mi)

+49 other locations

Age: 18+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Phase 2

Waitlist Available

Sponsor: Cerevance Beta, Inc.

Prior Safety Data

Trial Summary

What is the purpose of this trial?

This is a multicenter, 12-week, placebo-controlled clinical trial of CVN424 150 milligrams (mg) tablets in early, untreated Parkinson's Disease (PD). Participants will be randomized in a 1:1 ratio to CVN424 150 mg or placebo at the Baseline Visit. The purpose of this study is to measure effect on motor features with CVN424 tablets compared to placebo in early, untreated PD and to evaluate the potential of CVN424 to improve motor and non-motor functions in participants with early PD who are not taking dopaminergic or anti-PD therapies.

Research Team

Eligibility Criteria

This trial is for adults over 30 with early, untreated Parkinson's Disease who can walk (with or without help) and have mild to moderate disease severity. They shouldn't need Parkinson's medication during the study and must use reliable contraception if applicable. People with previous PD surgery, certain medical conditions, or recent use of specific drugs cannot join.

Inclusion Criteria

I have been diagnosed with Parkinson's disease, showing slow movement and motor asymmetry.

I am not on Parkinson's disease medication and don't expect to need it soon.

I am 30 years old or older.

See 6 more

Exclusion Criteria

I have not used marijuana in the last 2 months and will not use CBD during the study.

I experience significant dizziness when standing up.

Positive test for coronavirus disease 2019 (COVID-19). Confirmatory test will be allowed at the discretion of the Investigator to rule out false positives. A participant who tests positive for COVID-19 will be eligible to be rescreened once result is negative

See 23 more

Treatment Details

Interventions

CVN424 (Other)

Trial OverviewThe trial tests CVN424 (150 mg), a potential new treatment for Parkinson’s Disease symptoms against a placebo in patients not on other PD therapies. It aims to see if CVN424 improves motor and non-motor functions over 12 weeks compared to no active treatment.

Participant Groups

2Treatment groups

Experimental Treatment

Placebo Group

Group I: CVN424 150 mgExperimental Treatment1 Intervention

Participants will be administered with CVN424 150 mg.

Group II: PlaceboPlacebo Group1 Intervention

Participants will be administered with placebo.